ALLR Allarity Therapeutics, Inc.

$1.37

Allarity Therapeutics, Inc. (ALLR) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on August 14, 2026.

Allarity Therapeutics Beat Consensus Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · Before Open
Earnings Whisper
-
vs ($0.25)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.46

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Allarity Therapeutics, Inc.

Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.

Sector

Healthcare

Industry

Biotechnology